» Articles » PMID: 35955694

Reduced VDAC1, Maintained Mitochondrial Dynamics and Enhanced Mitochondrial Biogenesis in a Transgenic Tau Mouse Model of Alzheimer's Disease

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Aug 12
PMID 35955694
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is one of the most common forms of neurodegeneration, defined by reduced cognitive function, which is caused by the gradual death of neurons in the brain. Recent studies have shown an age-dependent rise in the levels of voltage-dependent anion channel 1 (VDAC1) in AD. In addition, we discovered an aberrant interaction between VDAC1 and P-TAU in the brains of AD patients, which led to abnormalities in the structural and functional integrity of the mitochondria. The purpose of our study is to understand the protective effects of reduced VDAC1 against impaired mitochondrial dynamics and defective mitochondrial biogenesis in transgenic TAU mice. Recently, we crossed heterozygote VDAC1 knockout (VDAC1) mice with transgenic TAU mice to obtain double-mutant VDAC1/TAU mice. Our goal was to evaluate whether a partial decrease in VDAC1 lessens the amount of mitochondrial toxicity in transgenic Tau (P301L) mice. We found that mitochondrial fission proteins were significantly reduced, and mitochondrial fusion and biogenesis proteins were increased in double-mutant mice compared to TAU mice. On the basis of these discoveries, the current work may have significance for the development of reduced-VDAC1-based treatments for individuals suffering from AD as well as other tauopathies.

Citing Articles

VDAC1: A Key Player in the Mitochondrial Landscape of Neurodegeneration.

Argueti-Ostrovsky S, Barel S, Kahn J, Israelson A Biomolecules. 2025; 15(1).

PMID: 39858428 PMC: 11762377. DOI: 10.3390/biom15010033.


Role of Mitochondrial Dysfunctions in Neurodegenerative Disorders: Advances in Mitochondrial Biology.

Kathiresan D, Balasubramani R, Marudhachalam K, Jaiswal P, Ramesh N, Sureshbabu S Mol Neurobiol. 2024; .

PMID: 39269547 DOI: 10.1007/s12035-024-04469-x.


Regulation of DNA damage response by RNA/DNA-binding proteins: Implications for neurological disorders and aging.

Kodavati M, Maloji Rao V, Provasek V, Hegde M Ageing Res Rev. 2024; 100:102413.

PMID: 39032612 PMC: 11463832. DOI: 10.1016/j.arr.2024.102413.


Mitochondrial alterations in fibroblasts from sporadic Alzheimer's disease (AD) patients correlate with AD-related clinical hallmarks.

Eysert F, Kinoshita P, Lagarde J, Lacas-Gervais S, Xicota L, Dorothee G Acta Neuropathol Commun. 2024; 12(1):90.

PMID: 38851733 PMC: 11161956. DOI: 10.1186/s40478-024-01807-x.


Mitochondria in Alzheimer's Disease Pathogenesis.

Reiss A, Gulkarov S, Jacob B, Srivastava A, Pinkhasov A, Gomolin I Life (Basel). 2024; 14(2).

PMID: 38398707 PMC: 10890468. DOI: 10.3390/life14020196.


References
1.
Colombini M . VDAC structure, selectivity, and dynamics. Biochim Biophys Acta. 2012; 1818(6):1457-65. PMC: 3327780. DOI: 10.1016/j.bbamem.2011.12.026. View

2.
Vijayan M, George M, Bunquin L, Bose C, Reddy P . Protective effects of a small-molecule inhibitor DDQ against tau-induced toxicities in a transgenic tau mouse model of Alzheimer's disease. Hum Mol Genet. 2021; 31(7):1022-1034. PMC: 8976431. DOI: 10.1093/hmg/ddab285. View

3.
Wang W, Zhao F, Ma X, Perry G, Zhu X . Mitochondria dysfunction in the pathogenesis of Alzheimer's disease: recent advances. Mol Neurodegener. 2020; 15(1):30. PMC: 7257174. DOI: 10.1186/s13024-020-00376-6. View

4.
Hirai K, Aliev G, Nunomura A, Fujioka H, Russell R, Atwood C . Mitochondrial abnormalities in Alzheimer's disease. J Neurosci. 2001; 21(9):3017-23. PMC: 6762571. View

5.
Fang E, Hou Y, Palikaras K, Adriaanse B, Kerr J, Yang B . Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nat Neurosci. 2019; 22(3):401-412. PMC: 6693625. DOI: 10.1038/s41593-018-0332-9. View